FDB (First Databank, Inc.)

In a recent interview with Managed Healthcare Executive, Lathe Bigler, vice president of clinical network services at FDB and general manager of FDB Vela™, an innovative, cloud-based ePrescribing network, discussed the critical role that prescription drug price transparency plays in improving medication adherence and patient outcomes, as well as reducing healthcare costs. Bigler highlighted that medication nonadherence is linked to increased mortality and healthcare expenses, totaling approximately $500 billion annually. Challenges such as inconsistent real-time pharmacy benefit data and limited access to drug out-of-pocket cost information hinder consumers' ability to make informed medication decisions and result in prescription abandonment at the pharmacy counter. However, Bigler remains optimistic that technological advancements and increased data access will enhance the consumer experiences, providing actionable insights and fostering better healthcare decisions. Bigler envisions FDB Vela as a pivotal tool in improving price transparency by collaborating with consumer applications to deliver critical drug pricing information to patients before the prescription fulfillment process. Tune in now to learn more: https://bit.ly/41vzR2G | #ePrescribing #PrescriptionDrugTransparency #MedicationAdherence #DrugKnowledge #PtSafety

To help you find the best option for relief from seasonal allergies Everyday Health spoke with board-certified experts to get their recommendations, insights, and to find out which OTC allergy medicines they trust and recommend to their patients. “Beyond stand-alone antihistamines, some allergy sufferers find relief by combining a decongestant with an antihistamine. Claritin-D is one of the best options on the market for this purpose because it targets common allergy symptoms in addition to the swelling that leads to sinus pressure and nasal congestion,” says Thomas So, PharmD, senior manager of the consumer drug information group at FDB.   Lindsay M. has the story: https://bit.ly/4gvbSoa | #DrugKnowledge #MedSafety #PtSafety #SeasonalAllergies

We're #hiring a new Security Architect in Indianapolis, Indiana. Apply today or share this post with your network.

More than 2,000 acute stroke patients with an indication for clopidogrel treatment have been genotyped in the UK’s first CYP2C19 genotyping project at NHS Tayside in Dundee, Scotland. Almost a third of people in the UK have a variant of the CYP2C19 gene, meaning that clopidogrel will not be as effective for them. “Anything we can do to prevent the misery that stroke can cause is ultimately good news. Getting on the right medication and taking it as advised is the best way for stroke survivors to reduce their risk of further strokes.” Sophie Willis has the story for Pharmaceutical Journal Publications: https://bit.ly/3B47sG6 | #GenotypingProject #Clopidogrel #Pharmacogenomics #DrugKnowledge

We're #hiring a new Security Operations Engineer in Indianapolis, Indiana. Apply today or share this post with your network.

In a new statement, the American Diabetes Association (ADA) has advised against the use of compounded glucagon-like peptide 1 receptor agonist (GLP-1 RA) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RA medication classes. “Compounded GLP-1 RA and dual GIP/GLP-1 RA products have been associated with clinically important dosing errors and adverse events. More concerning to individuals’ safety are counterfeit products that have made their way into the US drug supply chain and those advertised online and by unregulated sources,” the ADA said in the statement. Miriam E. Tucker has the story for Medscape: https://wb.md/4gdCESF | #DrugKnowledge #MedSafety #GLP1Meds #Pharmacists #DrugCompounding #HealthcareSupplyChain

As the demand to lower healthcare costs continues to grow, biosimilar development is advancing rapidly—sometimes faster than busy pharmacists can keep up. To meet this need, trusted and actionable biosimilar and interchangeable data is essential for making informed, cost-saving, and clinically appropriate therapy decisions. Join FDB at the ASHP Midyear Clinical Meeting and Exhibition where we’re showcasing the latest updates to our industry-leading FDB MedKnowledge® drug database! https://bit.ly/3CVzQKP ✨ What’s New? Our enhanced biologics tables and data elements are designed to streamline the clinician’s workflow by seamlessly grouping biologic products with their biosimilars and interchangeables. This innovative content enables users to: 💡 Quickly identify biosimilar and interchangeable options at both the prescribing concept and dispensing product (NDC) levels. 💡 Access detailed product attributes like ingredient, strength, dosage form, route, and proprietary/proper names. 💡 These enhancements empower pharmacists, prescribers, and insurers to efficiently navigate biologics data, enabling better decision-making and cost-saving strategies. 🧭 Visit FDB at Booth 1438 Explore how our trusted drug knowledge and solutions support pharmacists in enhancing patient care with: ➡ Trusted drug knowledge ➡ Medication decision support ➡ Patient medication education ➡ Streamlined workflows We look forward to seeing you! 💊 #DrugKnowledge #PharmacyInnovation #Biosimilars #HealthcareLeadership

📢 Two pharmacist experts from FDB will deliver quick and informative presentations during fast-paced “Pearls” educational sessions at the ASHP 2024 Midyear Clinical Meeting and Exhibition taking place from Dec. 8-12 in New Orleans.   🎙 Dr. Usha Desiraju, PharmD, manager of informatics and clinical content, will present during the “Informatics Pearls 2024: Gigabytes of Informatics,” session on Tuesday, Dec. 10, from 2-3 p.m. CST. Her presentation “Tomato, Tomahto: Bridging the Divide in Patient Care via EHR Interoperability,” is scheduled for 2:10 to 2:15 p.m. She will offer a brief overview of the many interoperability standards and normalized ontologies within electronic health records.   🎙 Dr. Kristin Buechler, PharmD, BCCCP, clinical informatics pharmacist, will present during the “Emergency Medicine Clinical Pearls 2024” session on Wednesday, Dec. 11, from 8-9:30 a.m. CST. The presentation “Gotta Let It Burn … Out,” is scheduled for 8:25 to 8:30 a.m. She will describe the high and growing professional burnout rate among health system pharmacists.   Learn more and join us for the sessions: https://bit.ly/4eFm0tp | #ASHP24 #ASHP2024 #ASHPpearls #PTCare #EHRInteroperability #PharmacistBurnout #BurnoutPrevention

Since the discovery of the HIV virus in the early 1980s, the last 40 years have seen exponential advancements regarding patient care in the HIV space. Jay Holloway, PharmD, AAHIVP, is a staff pharmacist with the AIDS Healthcare Foundation. He sat down with Drug Topics to discuss the current status of HIV care in the state of California and beyond. “HIV is, nowadays with our developments in medicine, a very manageable health condition. If you're adherent to your medications, then we can get you down to undetectable levels,” said Holloway. Brian Nowosielski has the story for Drug Topics: https://bit.ly/3OJukO0 | #Pharmacists #HIVTreatments #PrescriptionMeds #DrugDevelopment

A recent study concluded that for the nonopioid alternative agents that have been studied for acute opioid withdrawal, there is more evidence supporting the efficacy of α-adrenergic receptor agonists as opposed to NMDA antagonists, GABA modulators, or sertonergic agents; however, more research is needed regarding the efficacy and safety of nonopioid alternatives for acute opioid withdrawal in order to better guide clinical decision-making. Published in American Journal of Health-System Pharmacy. https://bit.ly/3VqvZfd | #OpioidCrisis #NonOpioid #DrugSafety #DrugKnowledge #MedSafety #PtSafety